EE43 Budget Impact Analysis of Favipiravir (AVIGAN®) for the Treatment of Patients with Confirmed Infection with SARS-COV2 in Mexico
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.295
https://www.valueinhealthjournal.com/article/S1098-3015(22)00496-X/fulltext
Title :
EE43 Budget Impact Analysis of Favipiravir (AVIGAN®) for the Treatment of Patients with Confirmed Infection with SARS-COV2 in Mexico
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00496-X&doi=10.1016/j.jval.2022.04.295
First page :
Section Title :
Open access? :
No
Section Order :
10259